Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypoparathyroidism.

N A Breslau, C Y Pak

    Metabolism: Clinical and Experimental
    |December 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Hypoparathyroidism stems from issues with parathyroid hormone (PTH) or vitamin D, affecting calcium homeostasis. Understanding these mechanisms clarifies treatment, with 1,25-dihydroxycholecalciferol (1,25-DHCC) offering a key therapeutic approach.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Role of medical approach in the management of stone disease.

    International journal of urology : official journal of the Japanese Urological Association·2013
    Same author

    Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis.

    Archives of internal medicine·2001
    Same author

    Biochemical profile of idiopathic uric acid nephrolithiasis.

    Kidney international·2001
    Same author

    The effect of calcium citrate on bone density in the early and mid-postmenopausal period: a randomized placebo-controlled study.

    American journal of therapeutics·2001
    Same author

    Adequacy of a single stone risk analysis in the medical evaluation of urolithiasis.

    The Journal of urology·2001
    Same author

    Pharmacokinetic and pharmacodynamic comparison of two calcium supplements in postmenopausal women.

    Journal of clinical pharmacology·2000
    Same journal

    Ablation of microglial estrogen receptor alpha predisposes male mice to diet-induced obesity.

    Metabolism: clinical and experimental·2026
    Same journal

    Pathophysiology-based subtypes of individuals at high-risk of type 2 diabetes: multi-omics profiles and lifestyle differences across subtypes.

    Metabolism: clinical and experimental·2026
    Same journal

    A thermosensitive TET-Parkin epigenetic axis couples mitochondrial quality control to adaptive thermogenesis in adipose tissue.

    Metabolism: clinical and experimental·2026
    Same journal

    Raffinose targets the NQO1/NF-κB axis to attenuate DON-driven microglial activation and neuroinflammation via metabolic reprogramming.

    Metabolism: clinical and experimental·2026
    Same journal

    Endothelial NPR-C promotes insulin resistance via Caveolin-1-mediated insulin transcytosis.

    Metabolism: clinical and experimental·2026
    Same journal

    Macrophage-enriched GPR91 aggravates acute liver injury by inhibiting efferocytosis via the AC/cAMP/PPARγ pathway.

    Metabolism: clinical and experimental·2026
    See all related articles

    Area of Science:

    • Endocrinology
    • Mineral Metabolism
    • Calcium Homeostasis

    Background:

    • Recent advances clarify hypoparathyroidism pathogenesis, classification, and management based on PTH and vitamin D physiology.
    • Hypoparathyroidism involves PTH deficiency, ineffectiveness, or resistance, impairing adenylate cyclase activity and calcium homeostasis.
    • Subnormal production of 1 alpha,25-dihydroxycholecalciferol (1,25-DHCC) is critical, impacting calcium and skeletal metabolism.

    Purpose of the Study:

    • To elucidate the role of PTH and vitamin D in hypoparathyroidism.
    • To categorize hypoparathyroidism based on PTH action and its impact on calcium homeostasis.
    • To highlight the therapeutic potential of 1,25-DHCC in managing hypoparathyroidism.

    Main Methods:

    • Review of current understanding of PTH and vitamin D physiology.

    Related Experiment Videos

  • Analysis of adenylate cyclase activity in target tissues.
  • Examination of 1 alpha-hydroxylase stimulation and 1,25-DHCC synthesis.

    • Main Results:

    • PTH deficiency/ineffectiveness impairs renal phosphate excretion and calcium reabsorption due to reduced adenylate cyclase activity.
    • Subnormal 1,25-DHCC production is linked to absent PTH and hypophosphatemia, potentially corrected by stimuli.
    • PTH resistance may involve primary defects in 1,25-DHCC synthesis, though some responses may improve.

    Conclusions:

    • Understanding PTH and vitamin D actions refines hypoparathyroidism classification and management.
    • Subnormal 1,25-DHCC production significantly affects calcium and skeletal metabolism.
    • Supplementation with 1,25-DHCC offers an effective therapeutic strategy for most hypoparathyroidism cases.